Landos Biopharma, Inc. (LABP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

1.0000

-0.0600

(-5.66%)

At close: 04:00PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Williams %R

View all chart patterns

Performance Outlook

Previous Close	1.0600
Open	1.0800
Bid	0.9200 x 900
Ask	1.0700 x 800
Day's Range	0.9100 - 1.0800
52 Week Range	0.5500 - 16.1700
Volume	99,426
Avg. Volume	104,243

Market Cap	40.255M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-1.0570
Earnings Date	Nov 14, 2022 - Nov 18, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	20.46

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for LABP

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Landos Biopharma, Inc.
Daily – Vickers Top Buyers & Sellers for 07/18/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Rating
Fair Value
Economic Moat
28 days agoArgus Research

All

Benzinga
Raymond James Is Bearish On This Inflammatory Bowel Disease Player On Upcoming 'Pipeline Reset'
Raymond James downgraded Landos Biopharma Inc (NASDAQ: LABP) to Market Perform from Outperform following 2Q22 earnings and the first look at NX-13 Phase 1b data in ulcerative colitis (UC). The analyst's rating change is driven by: Unclear strategy for omilancor in UC/Crohn's Disease (CD) (formulation optimization needed to improve solubility). Lack of conviction on NX-13's early efficacy data in UC until an adequately powered study is more clearly demonstrative of efficacy. The LAPB management t
GlobeNewswire
Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update
Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range of Once-Daily Oral Doses, as well as Promising Early Efficacy Signals Phase 2 Proof of Concept Clinical Trial for NX-13 in Ulcerative Colitis Planned On Track to Complete Comprehensive Review of Clinical Development Plans Later this Year NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical c
- VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options
  GlobeNewswire
- Embecta Corp. Reports Third Quarter Fiscal 2022 Financial Results
  GlobeNewswire
GlobeNewswire
Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial
NX-13 Demonstrated Favorable Safety and Tolerability Profile Across Range of Once-Daily Doses Results Indicate Promising Early Signals Regarding the Efficacy of NX-13 Phase 2 Proof of Concept Clinical Trial in Ulcerative Colitis Planned NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced positive top-line results from its Phase 1b clini